Optimal Stent Selection for the Femoropopliteal Artery

NCT ID: NCT02602145

Last Updated: 2023-08-29

Basic Information

• Recruitment Status: TERMINATED
• Total Enrollment: 5 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2014-09-02
• Study Completion Date: 2021-04-16

Brief Summary

Angioplasty and stenting for atherosclerotic occlusive disease in the arteries supplying the legs (Peripheral Arterial Disease, PAD) is the most common endovascular procedure outside of the heart, but carries the highest rate of reconstruction failure. The underlying reasons for these poor results are not completely clear, but the main arterial segment within the leg, the femoropopliteal artery, appears to be significantly different from other peripheral arteries because the Superficial Femoral Artery (SFA) and Popliteal Artery (PA) that comprise the femoropopliteal artery (FPA) segment, undergo large deformations during flexion of the limb. We propose to build mathematical models of human FPAs repaired with several frequently used PAD stents. These mathematical models would be able to assess the mechanical stress in the stented SFA and PA associated with limb flexion and predict disease recurrence for arteries with different patient and lesion characteristics. Results of model predictions will be validated in patients with PAD stents who have received these stents as part of their standard of care.

Detailed Description

This is an observational study of PAD patients that have already received SFA and PA stents as part of their standard of care.

The purpose of this study is to determine the effects of Peripheral Artery Disease (PAD) stenting on the femoropopliteal artery. This will be achieved through the following Specific Aims:

Aim 1. Evaluate pre-operative lower extremity CTAs of patients with PAD and determine the baseline arterial geometry and lesion characteristics.

Aim 2. Evaluate the results of intraoperative angiography and blood pressure measurements proximal and distal to the stent.

Aim 3. After stenting perform post-operative lower extremity CTA and assess the amount of in-stent restenosis and changes to the arterial geometry.

We propose to build mathematical models of human femoropopliteal arteries repaired with several of the most commonly used PAD stents and assess the mechanical stress associated with limb flexion. These models will aim at predicting disease recurrence for arteries with different patient and lesion characteristics.

Conditions

Femoropopliteal Stenting

Study Design

• Observational Model Type: OTHER
• Study Time Perspective: PROSPECTIVE

Study Groups

Peripheral artery disease patients

Patients with peripheral artery disease who were treated with a stent as part of their standard of care. Patients who meet the inclusion criteria (i.e. already have a stent in their femoropopliteal artery) will be consented after their endovascular repair, and those who choose to participate in the study will be followed for 6-12 months. During the follow-up, a post-operative contrast-enhanced CTA of the lower extremities will be obtained to assess for restenosis.

follow-up CTA

Intervention Type: OTHER

All patients will receive PAD stents as their normal standard of care determined by their treating physician. If the patient would decide to enroll in the study, we will perform a post-operative contrast-enhanced CTA of the lower extremities at 6-12 months after stenting.

Interventions

follow-up CTA

All patients will receive PAD stents as their normal standard of care determined by their treating physician. If the patient would decide to enroll in the study, we will perform a post-operative contrast-enhanced CTA of the lower extremities at 6-12 months after stenting.

Intervention Type: OTHER

Eligibility Criteria

Inclusion Criteria

• Subjects eligible for participating in this study are patients with severe PAD who have:

1. endovascular repair of their femoropopliteal artery

2. standard pre-operative contrast-enhanced thin-section CTA of the lower extremities

3. intraoperative angiograms and blood pressure measurements proximal and distal to the stent during the endovascular repair

4. no aneurysmal disease of the target femoropopliteal artery

5. no prior open or endovascular repair of the target femoropopliteal artery (patients with re-interventions are not eligible)

6. at least 2 out of 3 patent crural outflow vessels

7. life expectancy >6 months

8. no iodinated contrast allergy

9. creatinine less than 1.6 g/dL (unless on chronic dialysis, dialysis patients are eligible)

10. no orthopedic prostheses in the region of interest

11. ability to comply with 6-12-month follow-up contrast enhanced thin-section CTA

Exclusion Criteria

1. no endovascular repair of the femoropopliteal artery

2. endovascular or open re-intervention in the target limb

3. no pre-operative thin-section contrast-enhanced CTA of the target limb

4. no intraoperative angiogram or blood pressure measurements proximal and distal to the stent

5. aneurysmal disease of the target femoropopliteal artery

6. less than 2 patent crural outflow vessels

7. life expectancy ≤ 6 months

8. iodinated contrast allergy

9. orthopedic prosthesis in the region of interest

10. creatinine greater than 1.6 g/dL (unless dialysis patient, chronic dialysis patients are eligible)

11. inability to comply with 6-12-month contrast-enhanced CTA follow-up requirement

12. patient belongs to vulnerable population, i.e. pregnant women, prisoners, institutionalized individuals

• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

National Institutes of Health (NIH)

NIH

Sponsor Role: collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

Sponsor Role: collaborator

University of Nebraska

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Jason MacTaggart, MD

Role: PRINCIPAL_INVESTIGATOR

University of Nebraska

Locations

University of Nebraska Medical Center

Omaha, Nebraska, United States

Countries

United States

Other Identifiers

5R01HL125736-05

Identifier Type: NIH

Identifier Source: secondary_id

View Link

0386-14-FB

Identifier Type: -

Identifier Source: org_study_id